Pharmaceutical composition for viral infections

Abstract

Disclosed herein are topical compositions comprising a quaternary ammonium salt and optionally ammonium chloride and/or stabilized chlorine dioxide. Also disclosed herein are methods of reducing the severity and/or duration of a dermal and or mucosal infection such as herpes or shingles. Also disclosed herein are methods of preventing the spread of a viral infection such as HIV. Also disclosed herein are methods of treating a viral infection such as keratoconjunctivitis.

1 - 30 . (canceled) 
     
     
         31 . An anti-viral pharmaceutical composition comprising an active agent and a pharmaceutically acceptable carrier, wherein the active agent comprises C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride. 
     
     
         32 . The pharmaceutical composition of  claim 31 , wherein the composition is a topical composition. 
     
     
         33 . The pharmaceutical composition of  claim 31 , wherein the C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride is a mixture of C12-alkyl(ethylbenzyl)dimethylammonium chloride and C14-alkyl(ethylbenzyl)dimethylammonium chloride. 
     
     
         34 . The pharmaceutical composition of  claim 31 , wherein the C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride is C12-alkyl(ethylbenzyl)dimethylammonium chloride. 
     
     
         35 . The pharmaceutical composition of  claim 31 , wherein the C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride is C14-alkyl(ethylbenzyl)dimethylammonium chloride. 
     
     
         36 . The pharmaceutical composition of  claim 31 , wherein the pharmaceutical composition is essentially free of alkyl(ethylbenzyl)dimethyl ammonium salt having an alkyl of less than 12 carbons or more than 14 carbons. 
     
     
         37 . The pharmaceutical composition of  claim 31 , wherein the pharmaceutical composition is essentially free of benzalkonium chloride. 
     
     
         38 . The pharmaceutical composition of  claim 31 , wherein the C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride is present in an amount ranging from about 0.0001% to about 10% w/w. 
     
     
         39 . The pharmaceutical composition of  claim 31 , wherein the C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride is present in an amount ranging from about 0.001% to about 1% w/w. 
     
     
         40 . The pharmaceutical composition of claim  1 , wherein the pharmaceutical composition is in the form of an aerosol, a solution, a lotion, a gel, an ointment, a cream, a foam, a paste, or any combinations thereof. 
     
     
         41 . A pharmaceutical composition comprising an active agent and a pharmaceutically acceptable carrier, wherein the active agent consists of C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride. 
     
     
         42 . The pharmaceutical composition of  claim 41 , wherein the composition is a topical composition. 
     
     
         43 . The pharmaceutical composition of  claim 41 , wherein the active agent consists of C12-alkyl(ethylbenzyl)dimethylammonium chloride and C14-alkyl(ethylbenzyl)dimethylammonium chloride. 
     
     
         44 . The pharmaceutical composition of  claim 41 , wherein the active agent consists of C12-alkyl(ethylbenzyl)dimethylammonium chloride. 
     
     
         45 . The pharmaceutical composition of  claim 41 , wherein the active agent consists of C14-alkyl(ethylbenzyl)dimethylammonium chloride. 
     
     
         46 . The pharmaceutical composition of  claim 41 , wherein the pharmaceutical composition is essentially free of benzalkonium chloride. 
     
     
         47 . The pharmaceutical composition of  claim 41 , wherein the C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride is present in an amount ranging from about 0.0001% to about 10% w/w. 
     
     
         48 . The pharmaceutical composition of  claim 41 , wherein the C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride is present in an amount ranging from about 0.001% to about 1% w/w. 
     
     
         49 . The pharmaceutical composition of  claim 41 , wherein the pharmaceutical composition is in the form of an aerosol, a solution, a lotion, a gel, an ointment, a cream, a foam, a paste, or any combinations thereof. 
     
     
         50 . A method of treating an infectious disease or condition by administering a pharmaceutical composition of  claim 41 . 
     
     
         51 . The method of  claim 50 , wherein the infectious disease or condition is selected from the group consisting of cold sores, genital herpes, shingles, herpetic simplex keratitis, epidemic keratoconjunctivitis, Ebola, influenza, chickenpox, and AIDS.